The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
CD109 (Cluster of Differentiation 109) is a human gene.[1]
CD109 is a GPI-linked cell surface antigen expressed by CD34+ acute myeloid leukemia cell lines, T-cell lines, activated T lymphoblasts, endothelial cells, and activated platelets (Lin et al., 2002). In addition, the platelet-specific Gov antigen system, implicated in refractoriness to platelet transfusion, neonatal alloimmune thrombocytopenia, and posttransfusion purpura, is carried by CD109 (Kelton et al., 1990; Lin et al., 2002).[supplied by OMIM][1]
Lucas GF, Metcalfe P (2000). "Platelet and granulocyte glycoprotein polymorphisms". Transfusion medicine (Oxford, England). 10 (3): 157–74. doi:10.1046/j.1365-3148.2000.00250.x. PMID10972910.
Sutherland DR, Yeo E, Ryan A, et al. (1991). "Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets". Blood. 77 (1): 84–93. PMID1984805.
Kelton JG, Smith JW, Horsewood P, et al. (1990). "Gova/b alloantigen system on human platelets". Blood. 75 (11): 2172–6. PMID2346781.
Lin M, Sutherland DR, Horsfall W, et al. (2002). "Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins". Blood. 99 (5): 1683–91. doi:10.1182/blood.V99.5.1683. PMID11861284.
Schuh AC, Watkins NA, Nguyen Q, et al. (2002). "A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens". Blood. 99 (5): 1692–8. doi:10.1182/blood.V99.5.1692. PMID11861285.
Giesert C, Marxer A, Sutherland DR, et al. (2003). "Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34- hematopoietic and mesenchymal stem cell subsets". Ann. N. Y. Acad. Sci. 996: 227–30. doi:10.1111/j.1749-6632.2003.tb03250.x. PMID12799300.
Mungall AJ, Palmer SA, Sims SK, et al. (2003). "The DNA sequence and analysis of human chromosome 6". Nature. 425 (6960): 805–11. doi:10.1038/nature02055. PMID14574404.
Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID14702039.
Solomon KR, Sharma P, Chan M, et al. (2004). "CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family". Gene. 327 (2): 171–83. doi:10.1016/j.gene.2003.11.025. PMID14980714.
Zhang JM, Hashimoto M, Kawai K, et al. (2005). "CD109 expression in squamous cell carcinoma of the uterine cervix". Pathol. Int. 55 (4): 165–9. doi:10.1111/j.1440-1827.2005.01807.x. PMID15826242.
Lewandrowski U, Moebius J, Walter U, Sickmann A (2006). "Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach". Mol. Cell. Proteomics. 5 (2): 226–33. doi:10.1074/mcp.M500324-MCP200. PMID16263699.
Finnson KW, Tam BY, Liu K, et al. (2006). "Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes". FASEB J. 20 (9): 1525–7. doi:10.1096/fj.05-5229fje. PMID16754747.
Sjöblom T, Jones S, Wood LD, et al. (2006). "The consensus coding sequences of human breast and colorectal cancers". Science. 314 (5797): 268–74. doi:10.1126/science.1133427. PMID16959974.
Hasegawa M, Hagiwara S, Sato T, et al. (2007). "CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells". Pathol. Int. 57 (5): 245–50. doi:10.1111/j.1440-1827.2007.02097.x. PMID17493171.